监测甲状腺结节退伍军人体内的促甲状腺素

Sabrina Kaul, Ankur Gupta
{"title":"监测甲状腺结节退伍军人体内的促甲状腺素","authors":"Sabrina Kaul, Ankur Gupta","doi":"10.12788/fp.0431","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>After the initial thyroid nodule diagnosis, a patient's thyrotropin is often monitored. However, the American Thyroid Association guidelines do not offer recommendations for follow-up thyrotropin testing for patients with thyroid nodules who have no history of conditions or known medications that affect thyroid hormone levels.</p><p><strong>Methods: </strong>At the Veterans Affairs Dayton Healthcare System in Ohio, we conducted a retrospective chart review from January 2010 to December 2016 of 100 patients diagnosed with ≥ 1 thyroid nodule on imaging studies who had normal blood thyrotropin at the time of nodule diagnosis. The thyrotropin value was studied at and after diagnosis. A 95% CI was determined for the true population rate of patients with an abnormal thyrotropin at their most recent testing. χ<sup>2</sup> tests for categorical variables and independent sample <i>t</i> tests for continuous variables were used to compare the abnormal and normal most recent thyrotropin groups.</p><p><strong>Results: </strong>One hundred patients (male [83%], White race [82%]) with normal thyrotropin at nodule diagnosis had thyrotropin monitoring for a mean (SD) of 5.7 (2.5) years. Six of 100 patients (6%; 95% CI, 2.5%-12.7%) developed abnormal thyrotropin levels in a mean (SD) of 6.9 (3.1) years. When comparing the 6 patients with abnormal thyrotropin vs the 94 with normal thyrotropin, there were no significant differences in sex (<i>P</i> = .99), race (<i>P</i> = .55), age at diagnosis (<i>P</i> = .12), initial thyrotropin level (<i>P</i> = .24), most recent thyrotropin level (<i>P</i> = .98), or time from diagnosis to most recent thyrotropin level (<i>P</i> = .23).</p><p><strong>Conclusions: </strong>This study found no significant change in thyrotropin levels over time in patients with thyroid nodules and no history of medical conditions or medications known to affect thyrotropin levels. Monitoring thyrotropin over time may not be required in these patients. More studies are needed to provide additional data on thyrotropin monitoring for thyroid nodules so that clinicians can make evidence-based decisions.</p>","PeriodicalId":94009,"journal":{"name":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984678/pdf/","citationCount":"0","resultStr":"{\"title\":\"Monitoring Thyrotropin in Veterans With Thyroid Nodules.\",\"authors\":\"Sabrina Kaul, Ankur Gupta\",\"doi\":\"10.12788/fp.0431\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>After the initial thyroid nodule diagnosis, a patient's thyrotropin is often monitored. However, the American Thyroid Association guidelines do not offer recommendations for follow-up thyrotropin testing for patients with thyroid nodules who have no history of conditions or known medications that affect thyroid hormone levels.</p><p><strong>Methods: </strong>At the Veterans Affairs Dayton Healthcare System in Ohio, we conducted a retrospective chart review from January 2010 to December 2016 of 100 patients diagnosed with ≥ 1 thyroid nodule on imaging studies who had normal blood thyrotropin at the time of nodule diagnosis. The thyrotropin value was studied at and after diagnosis. A 95% CI was determined for the true population rate of patients with an abnormal thyrotropin at their most recent testing. χ<sup>2</sup> tests for categorical variables and independent sample <i>t</i> tests for continuous variables were used to compare the abnormal and normal most recent thyrotropin groups.</p><p><strong>Results: </strong>One hundred patients (male [83%], White race [82%]) with normal thyrotropin at nodule diagnosis had thyrotropin monitoring for a mean (SD) of 5.7 (2.5) years. Six of 100 patients (6%; 95% CI, 2.5%-12.7%) developed abnormal thyrotropin levels in a mean (SD) of 6.9 (3.1) years. When comparing the 6 patients with abnormal thyrotropin vs the 94 with normal thyrotropin, there were no significant differences in sex (<i>P</i> = .99), race (<i>P</i> = .55), age at diagnosis (<i>P</i> = .12), initial thyrotropin level (<i>P</i> = .24), most recent thyrotropin level (<i>P</i> = .98), or time from diagnosis to most recent thyrotropin level (<i>P</i> = .23).</p><p><strong>Conclusions: </strong>This study found no significant change in thyrotropin levels over time in patients with thyroid nodules and no history of medical conditions or medications known to affect thyrotropin levels. Monitoring thyrotropin over time may not be required in these patients. More studies are needed to provide additional data on thyrotropin monitoring for thyroid nodules so that clinicians can make evidence-based decisions.</p>\",\"PeriodicalId\":94009,\"journal\":{\"name\":\"Federal practitioner : for the health care professionals of the VA, DoD, and PHS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984678/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Federal practitioner : for the health care professionals of the VA, DoD, and PHS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12788/fp.0431\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Federal practitioner : for the health care professionals of the VA, DoD, and PHS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/fp.0431","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:在初次诊断甲状腺结节后,通常会对患者的甲状腺素进行监测。然而,美国甲状腺协会指南并没有建议对没有影响甲状腺激素水平的病史或已知药物的甲状腺结节患者进行甲状腺素随访检测:在俄亥俄州的退伍军人事务代顿医疗保健系统,我们从 2010 年 1 月至 2016 年 12 月对 100 名经影像学检查确诊有≥1 个甲状腺结节的患者进行了回顾性病历审查,这些患者在结节确诊时血液甲状腺素正常。对诊断时和诊断后的甲状腺素值进行了研究。对分类变量进行χ2检验,对连续变量进行独立样本t检验,以比较甲状腺素异常组和甲状腺素正常组:100名确诊甲状腺结节时促甲状腺激素正常的患者(男性[83%],白种人[82%])接受了平均(标度)5.7(2.5)年的促甲状腺激素监测。100 名患者中有 6 人(6%;95% CI,2.5%-12.7%)在平均(标清)6.9(3.1)年的时间内出现甲状腺素水平异常。将甲状腺素异常的 6 名患者与甲状腺素正常的 94 名患者进行比较,性别(P = .99)、种族(P = .55)、诊断年龄(P = .12)、初始甲状腺素水平(P = .24)、最近甲状腺素水平(P = .98)或从诊断到最近甲状腺素水平的时间(P = .23)均无显著差异:本研究发现,甲状腺结节患者的甲状腺素水平随着时间的推移无明显变化,且无已知会影响甲状腺素水平的病史或药物史。这些患者可能不需要长期监测甲状腺素。需要更多的研究来提供更多有关甲状腺结节甲状腺素监测的数据,以便临床医生做出循证决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Monitoring Thyrotropin in Veterans With Thyroid Nodules.

Background: After the initial thyroid nodule diagnosis, a patient's thyrotropin is often monitored. However, the American Thyroid Association guidelines do not offer recommendations for follow-up thyrotropin testing for patients with thyroid nodules who have no history of conditions or known medications that affect thyroid hormone levels.

Methods: At the Veterans Affairs Dayton Healthcare System in Ohio, we conducted a retrospective chart review from January 2010 to December 2016 of 100 patients diagnosed with ≥ 1 thyroid nodule on imaging studies who had normal blood thyrotropin at the time of nodule diagnosis. The thyrotropin value was studied at and after diagnosis. A 95% CI was determined for the true population rate of patients with an abnormal thyrotropin at their most recent testing. χ2 tests for categorical variables and independent sample t tests for continuous variables were used to compare the abnormal and normal most recent thyrotropin groups.

Results: One hundred patients (male [83%], White race [82%]) with normal thyrotropin at nodule diagnosis had thyrotropin monitoring for a mean (SD) of 5.7 (2.5) years. Six of 100 patients (6%; 95% CI, 2.5%-12.7%) developed abnormal thyrotropin levels in a mean (SD) of 6.9 (3.1) years. When comparing the 6 patients with abnormal thyrotropin vs the 94 with normal thyrotropin, there were no significant differences in sex (P = .99), race (P = .55), age at diagnosis (P = .12), initial thyrotropin level (P = .24), most recent thyrotropin level (P = .98), or time from diagnosis to most recent thyrotropin level (P = .23).

Conclusions: This study found no significant change in thyrotropin levels over time in patients with thyroid nodules and no history of medical conditions or medications known to affect thyrotropin levels. Monitoring thyrotropin over time may not be required in these patients. More studies are needed to provide additional data on thyrotropin monitoring for thyroid nodules so that clinicians can make evidence-based decisions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A Crisis in Scope: Recruitment and Retention Challenges Reported by VA Gastroenterology Section Chiefs. Has the VA Fulfilled its Commitment to Trust and Healing? I*DEA in the VA: Optimizing the Physician Workforce to Enhance Quality of Care. Acquired Factor VIII Deficiency Presenting as Compartment Syndrome. Impact of VA Hematology/Oncology Clinical Pharmacy Practitioners in the Review of Community Prescriptions for Specialty Medications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1